Lipoprotein-associated phospholipase A2 (Lp-PLA2): A review of its role and significance as a cardiovascular biomarker

Biomarkers

Volumn 17, Issue 4, 2012, Pages 289-302

  Vittos, Oana ^a,b   Toana, Bogdan ^c   Vittos, Alexandros ^a   Moldoveanu, Elena ^d,e  

^a Center of Excellence in Laboratory Medicine and Pathology   (Romania)

^b CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c Carol Davila Central Military Emergency Hospital   (Romania)

^d VICTOR BABES NATIONAL INSTITUTE OF PATHOLOGY   (Romania)

^e TITU MAIORESCU UNIVERSITY   (Romania)

Author keywords

Cardiovascular disease; Growth factors cytokines inflammatory mediators; Oxidative stress

Indexed keywords

ACETYLSALICYLIC ACID; APOLIPOPROTEIN B; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CHOLESTEROL; DIGITALIS; EZETIMIBE; FENOFIBRATE; GAMMA INTERFERON; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIPOPROTEIN ASSOCIATED PHOSPHOLIPASE A2 PROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LYSOPHOSPHATIDYLCHOLINE; LYSOPHOSPHOLIPID; MEVINOLIN; PHOSPHOLIPASE A2; PLATELET DERIVED GROWTH FACTOR; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TETRAHYDROLIPSTATIN; THROMBOCYTE ACTIVATING FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VERY LOW DENSITY LIPOPROTEIN;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONGESTIVE HEART FAILURE; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY BYPASS SURGERY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; DRUG EFFICACY; DYSLIPIDEMIA; ENZYME ACTIVITY; HEART DEATH; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART TRANSPLANTATION; HUMAN; ISCHEMIC HEART DISEASE; LOW FAT DIET; MORTALITY; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW; RISK ASSESSMENT; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STROKE; TRANSIENT ISCHEMIC ATTACK; TRANSLUMINAL CORONARY ANGIOPLASTY; UNSTABLE ANGINA PECTORIS; VASCULITIS;

1-ALKYL-2-ACETYLGLYCEROPHOSPHOCHOLINE ESTERASE; BIOLOGICAL MARKERS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION MEDIATORS; LIPOPROTEINS; MOLECULAR TARGETED THERAPY; OXIDATIVE STRESS;

EID: 84861631409     PISSN: 1354750X     EISSN: 13665804     Source Type: Journal    
DOI: 10.3109/1354750X.2012.664170     Document Type: Review

References (91)

1. Ali M, Madjid M. (2009). Lipoprotein-associated phospholipase A2: a cardiovascular risk predictor and a potential therapeutic target. Future Cardiol 5:159-173.
2. Anderson JL. (2008). Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention. Am J Cardiol 101:23F-33F.
3. Asano K, Okamoto S, Fukunaga K, Shiomi T, Mori T, Iwata M, Ikeda Y, Yamaguchi K. (1999). Cellular source(s) of platelet-activatingfactor acetylhydrolase activity in plasma. Biochem Biophys Res Commun 261:511-514.
4. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Heiss G, Sharrett AR. (2004). Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Circulation 109:837-842.
5. Ballantyne CM, Hoogeveen RC, Bang H, Coresh J, Folsom AR, Chambless LE, Myerson M, Wu KK, Sharrett AR, Boerwinkle E. (2005). Lipoprotein-associated phospholipase A2, highsensitivity C-reactive protein, and risk for incident ischemic stroke in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study. Arch Intern Med 165:2479-2484.
6. Balsinde J, Bianco ID, Ackermann EJ, Conde-Frieboes K, Dennis EA. (1995). Inhibition of calcium-independent phospholipase A2 prevents arachidonic acid incorporation and phospholipid remodeling in P388D1 macrophages. Proc Natl Acad Sci USA 92:8527-8531.
7. Basu A, Jensen MD, McCann F, Nandy D, Mukhopadhyay D, McConnell JP, Rizza RA. (2007). Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes. Endocr Pract 13:147-152.
8. Biomarkers Definitions Working Group. (2001). Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 69:89-95.
9. Braun LT, Davidson MH. (2010). Lp-PLA2: A new target for statin therapy. Curr Atheroscler Rep 12:29-33.
10. Brilakis ES, McConnell JP, Lennon RJ, Elesber AA, Meyer JG, Berger PB. (2005). Association of lipoprotein-associated phospholipase A2 levels with coronary artery disease risk factors, angiographic coronary artery disease, and major adverse events at follow-up. Eur Heart J 26:137-144.
11. Carpenter KL, Dennis IF, Challis IR, Osborn DP, Macphee CH, Leake DS, Arends MJ, Mitchinson MJ. (2001). Inhibition of lipoproteinassociated phospholipase A2 diminishes the death-inducing effects of oxidised LDL on human monocyte-macrophages. FEBS Lett 505:357-363.
12. Castelli WP. (1996). Lipids, risk factors and ischaemic heart disease. Atherosclerosis 124 Suppl:S1-S9.
13. Charo IF, Taub R. (2011). Anti-inflammatory therapeutics for the treatment of atherosclerosis. Nat Rev Drug Discov 10:365-376.
14. Colley KJ, Wolfert RL, Cobble ME. (2011). Lipoprotein associated phospholipase A(2): role in atherosclerosis and utility as a biomarker for cardiovascular risk. EPMA J 2:27-38.
15. Corson MA, Jones PH, Davidson MH. (2008). Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker. Am J Cardiol 101:41F-50F.
16. Daniels LB, Laughlin GA, Sarno MJ, Bettencourt R, Wolfert RL, Barrett-Connor E. (2008). Lipoprotein-associated phospholipase A2 is an independent predictor of incident coronary heart disease in an apparently healthy older population: the Rancho Bernardo Study. J Am Coll Cardiol 51:913-919.
17. Davidson MH, Corson MA, Alberts MJ, Anderson JL, Gorelick PB, Jones PH, Lerman A, McConnell JP, Weintraub HS. (2008). Consensus panel recommendation for incorporating lipoproteinassociated phospholipase A2 testing into cardiovascular disease risk assessment guidelines. Am J Cardiol 101:51F-57F.
18. Elkind MS, Tai W, Coates K, Paik MC, Sacco RL. (2006). High-sensitivity C-reactive protein, lipoprotein-associated phospholipase A2, and outcome after ischemic stroke. Arch Intern Med 166:2073-2080.
19. Evans JH, Leslie CC. (2004). The cytosolic phospholipase A2 catalytic domain modulates association and residence time at Golgi membranes. J Biol Chem 279:6005-6016.
20. Filippatos TD, Gazi IF, Liberopoulos EN, Athyros VG, Elisaf MS, Tselepis AD, Kiortsis DN. (2007). The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome. Atherosclerosis 193:428-437.
21. Furberg CD, Nelson JJ, Solomon C, Cushman M, Jenny NS, Psaty BM. (2008). Distribution and correlates of lipoprotein-associated phospholipase A2 in an elderly cohort: the Cardiovascular Health Study. J Am Geriatr Soc 56:792-799.
22. Gardner AA, Reichert EC, Topham MK, Stafforini DM. (2008). Identification of a domain that mediates association of plateletactivating factor acetylhydrolase with high density lipoprotein. J Biol Chem 283:17099-17106.
23. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo IJ, Lopez- Jimenez F. (2007). Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 82:159-165.
24. Gazi I, Lourida ES, Filippatos T, Tsimihodimos V, Elisaf M, Tselepis AD. (2005). Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem 51:2264-2273.
25. Gerber Y, Dunlay SM, Jaffe AS, McConnell JP, Weston SA, Killian JM, Roger VL. (2009). Plasma lipoprotein-associated phospholipase A2 levels in heart failure: association with mortality in the community. Atherosclerosis 203:593-598.
26. Greenland P, Knoll MD, Stamler J, Neaton JD, Dyer AR, Garside DB, Wilson PW. (2003). Major risk factors as antecedents of fatal and nonfatal coronary heart disease events. JAMA 290:891-897.
27. Hatoum I, CookN, Nelson J, Rexrode K, Rimm E . Lipoprotein-associated phospholipase A(2) activity improves risk discrimination of incident coronary heart disease among women. Am Heart J 2011;161:516-522. DOI: 10.1016/j.ahj.2010.11.007
28. Hatoum IJ, Nelson JJ, Cook NR, Hu FB, Rimm EB. (2010). Dietary, lifestyle, and clinical predictors of lipoprotein-associated phospholipase A2 activity in individuals without coronary artery disease. Am J Clin Nutr 91:786-793.
29. Hiraoka M, Abe A, Shayman JA. (2005). Structure and function of lysosomal phospholipase A2: identification of the catalytic triad and the role of cysteine residues. J Lipid Res 46:2441-2447.
30. Jenny NS, Solomon C, Cushman M, Tracy RP, Nelson JJ, Psaty BM, Furberg CD. (2010). Lipoprotein-associated phospholipase A(2) (Lp-PLA(2)) and risk of cardiovascular disease in older adults: results from the Cardiovascular Health Study. Atherosclerosis 209:528-532.
31. Kardys I, Oei HH, Hofman A, Oudkerk M, Witteman JC. (2007). Lipoprotein-associated phospholipase A2 and coronary calcification. The Rotterdam Coronary Calcification Study. Atherosclerosis 191:377-383.
32. Kardys I, Oei HH, van der Meer IM, Hofman A, Breteler MM, Witteman JC. (2006). Lipoprotein-associated phospholipase A2 and measures of extracoronary atherosclerosis: the Rotterdam Study. Arterioscler Thromb Vasc Biol 26:631-636.
33. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, Ellis SG, Lincoff AM, Topol EJ. (2003). Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 290:898-904.
34. Koenig W, Khuseyinova N, Lowel H, Trischler G, Meisinger C. (2004). Lipoprotein-associated phospholipase A2 adds to risk prediction of incident coronary events by C-reactive protein in apparently healthy middle-aged men from the general population: results from the 14-year follow-up of a large cohort from southern Germany. Circulation 110:1903-1908.
35. Koenig W, Twardella D, Brenner H, Rothenbacher D. (2006). Lipoprotein-associated phospholipase A2 predicts future cardiovascular events in patients with coronary heart disease independently of traditional risk factors, markers of inflammation, renal function, and hemodynamic stress. Arterioscler Thromb Vasc Biol. 26:1586-1593. Epub 2006 Apr 20.
36. Korkmaz L, Erkus E, Kiris A, Agac MT, Acar Z, Turan T, Erkan H, Dursun I, Celik S. (2011). Lipoprotein phospholipase A2 in patients with isolated coronary artery ectasia. Clin Res Cardiol 100:511-514.
37. Kolodgie FD, Burke AP, Skorija KS, Ladich E, Kutys R, Makuria AT, Virmani R. (2006). Lipoprotein-associated phospholipase A2 protein expression in the natural progression of human coronary atherosclerosis. Arterioscler Thromb Vasc Biol 26:2523-2529.
38. Kom GD, Schwedhelm E, Maas R, Schneider L, Benndorf R, Boger RH. (2007). Impact of atorvastatin treatment on plateletactivating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients. Br J Clin Pharmacol 63:672-679.
39. Ky B, Burke A, Tsimikas S, Wolfe ML, Tadesse MG, Szapary PO, Witztum JL, FitzGerald GA, Rader DJ. (2008). The influence of pravastatin and atorvastatin on markers of oxidative stress in hypercholesterolemic humans. J Am Coll Cardiol 51:1653-1662.
40. Lourida ES, Papathanasiou AI, Goudevenos JA, Tselepis AD. (2006). The low-density lipoprotein (LDL)-associated PAF-acetylhydrolase activity and the extent of LDL oxidation are important determinants of the autoantibody titers against oxidized LDL in patients with coronary artery disease. Prostaglandins Leukot Essent Fatty Acids 75:117-126.
41. Macphee CH, Nelsonj JJ, Zalewski A. (2005). Lipoprotein-associated phospholipase A2 as a target of therapy. Curr. Opin. Lipidol. 16:4442-4446.
42. Mannheim D, Herrmann J, Versari D, Gossl M, Meyer FB, McConnell JP, Lerman LO, Lerman A. (2008). Enhanced expression of Lp-PLA2 and lysophosphatidylcholine in symptomatic carotid atherosclerotic plaques. Stroke 39:1448-1455.
43. May HT, Horne BD, Anderson JL, Wolfert RL, Muhlestein JB, Renlund DG, Clarke JL, Kolek MJ, Bair TL, Pearson RR, Sudhir K, Carlquist JF. (2006). Lipoprotein-associated phospholipase A2 independently predicts the angiographic diagnosis of coronary artery disease and coronary death. Am Heart J 152:997-1003.
44. McCullough PA. (2009). Darapladib and atherosclerotic plaque: should lipoprotein-associated phospholipase A2 be a therapeutic target? Curr Atheroscler Rep 11:334-337.
45. McIntyre TM, Prescott SM, Stafforini DM. (2009). The emerging roles of PAF acetylhydrolase. J Lipid Res 50 Suppl:S255-S259.
46. Min JH, Jain MK, Wilder C, Paul L, Apitz-Castro R, Aspleaf DC, Gelb MH. (1999). Membrane-bound plasma platelet activating factor acetylhydrolase acts on substrate in the aqueous phase. Biochemistry 38:12935-12942.
47. Miyaura S, Maki N, Byrd W, Johnston JM. (1991). The hormonal regulation of platelet-activating factor acetylhydrolase activity in plasma. Lipids 26:1015-1020.
48. Moldoveanu E, Serban M, Marta D, Serban I, Huica R. (2011). Lipoprotein associated phospholipase A2 in patients with preserved left ventricular ejection fraction. Biomarkers 2194-2556.
49. Moran JM, Buller RML, McHowat J, Turk J, Wohltmann M, Gross RW, Corbett JA. (2005). Genetic and pharmacologic evidence that calcium-independent phospholipase A2 beta regulates virus-induced inducible nitric-oxide synthase expression by macrophages. J Biol Chem 280:28162-28168.
50. O'Donoghue M, Morrow DA, Sabatine MS, Murphy SA, McCabe CH, Cannon CP, Braunwald E. (2006). Lipoprotein associated A2 and its association with cardiovascular outcomes in patients with acute coronary syndromes in the PROVE IT-TIMI 22 (PRavastatin Or atorVastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction) trial. Circulation 113:1745-1752.
51. Oei HH, van der Meer IM, Hofman A, Koudstaal PJ, Stijnen T, Breteler MM, Witteman JC. (2005). Lipoprotein-associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: the Rotterdam Study. Circulation 111:570-575.
52. Ohshige A, Ito M, Koyama H, Maeda T, Yoshimura T, Okamura H. (1994). Effects of estrogen and progesterone on plateletactivating factor acetylhydrolase activity in ovariectomised rats. Artery 21:234-242.
53. Orem C, Kahraman N, Orem A, Ucar U, Yucesan FB, Mentese A. (2011). Increased plasma lipoprotein-associated phospholipase A2 (Lp-PLA2) levels are related to good collateral development in patients with isolated left coronary artery disease. Int J Cardiol 148:117-119.
54. Packard CJ, O'Reilly DS, Caslake MJ, McMahon AD, Ford I, Cooney J, Macphee CH, Suckling KE, Krishna M, Wilkinson FE, Rumley A, Lowe GD. (2000). Lipoprotein-associated phospholipase A2 as an independent predictor of coronary heart disease. West of Scotland Coronary Prevention Study Group. N Engl J Med 343:1148-1155.
55. Persson M, Berglund G, Nelson JJ, Hedblad B. (2008). Lp-PLA2 activity and mass are associated with increased incidence of ischemic stroke: a population-based cohort study from Malmo, Sweden. Atherosclerosis 200:191-198.
56. Persson M, Hedblad B, Nelson JJ, Berglund G. (2007). Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol 27:1411-1416.
57. Persson M, Nilsson JA, Nelson JJ, Hedblad B, Berglund G. (2007). The epidemiology of Lp-PLA(2): distribution and correlation with cardiovascular risk factors in a population-based cohort. Atherosclerosis 190:388-396.
58. Raichlin E, McConnell JP, Bae JH, Kremers WK, Lerman A, Frantz RP. (2008). Lipoprotein-associated phospholipase A2 predicts progression of cardiac allograft vasculopathy and increased risk of cardiovascular events in heart transplant patients. Transplantation 85:963-968.
59. Ridker P, Cannon C, Morrow D, Rifai N, Rose L, McCabe C, Pfeffer M, Braunwald E. (2005). C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352:20-28.
60. Rosenson RS. (2008). Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome. Am Heart J 155:499.e9-499.16.
61. Sabatine MS, Morrow DA, O'Donoghue M, Jablonksi KA, Rice MM, Solomon S, Rosenberg Y, Domanski MJ, Hsia J; PEACE Investigators. (2007). Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease. Arterioscler Thromb Vasc Biol 27:2463-2469.
62. Saougos VG, Tambaki AP, Kalogirou M, Kostapanos M, Gazi IF, Wolfert RL, Elisaf M, Tselepis AD. (2007). Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2. Arterioscler Thromb Vasc Biol 27:2236-2243.
63. Sarlon-BartoliBoudes, A, Buffat C, Bartoli MA, Piercecchi-Marti MD, Sarlon E, Arnaud L, Bennis Y, Thevenin B, Squarcioni C, Nicoli F, Dignat-George F, Sabatier F, Magnan PE. Circulating Lipoproteinassociated Phospholipase A2 in High-grade Carotid Stenosis: A New Biomarker for Predicting Unstable Plaque. Eur J Vasc Endovasc Surg. 2011 Nov 8. [Epub ahead of print]
64. Satake Y, Diaz BL, Balestrieri B, Lam BK, Kanaoka Y, Grusby MJ, Arm JP. (2004). Role of group V phospholipase A2 in zymosan-induced eicosanoid generation and vascular permeability revealed by targeted gene disruption. J Biol Chem 279:16488-16494.
65. Schaefer EJ, McNamara JR, Asztalos BF, Tayler T, Daly JA, Gleason JL, Seman LJ, Ferrari A, Rubenstein JJ. (2005). Effects of atorvastatin versus other statins on fasting and postprandial C-reactive protein and lipoprotein- associated phospholipase A2 in patients with coronary heart disease versus control subjects. Am J Cardiol 95:1025-1032.
66. Schaloske RH, Dennis EA. (2006). The phospholipase A2 superfamily and its group numbering system. Biochim Biophys Acta 1761:1246-1259.
67. Serruys PW, Garcia-Garcia HM, Buszman P, Erne P, Verheye S, Aschermann M, Duckers H, Bleie O, Dudek D, Botker HE, von Birgelen C, D'Amico D, Hutchinson T, Zambanini A, Mastik F, van Es GA, van der Steen AF, Vince DG, Ganz P, Hamm CW, Wijns W, Zalewski A; Integrated Biomarker and Imaging Study-2 Investigators. (2008). Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque. Circulation 118:1172-1182.
68. Shirai Y, Balsinde J, Dennis EA. (2005). Localization and functional interrelationships among cytosolic Group IV, secreted Group V, and Ca2+-independent Group VI phospholipase A2s in P388D1 macrophages using GFP/RFP constructs. Biochim Biophys Acta 1735:119-129.
69. Silva IT, Mello AP, Damasceno NR. (2011). Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A2 (Lp-PLA2): a review. Lipids Health Dis 10:170.
70. Six DA, Dennis EA. (2000). The expanding superfamily of phospholipase A(2) enzymes: classification and characterization. Biochim Biophys Acta 1488:1-19.
71. Stafforini DM, McIntyre TM, Carter ME, Prescott SM. (1987). Human plasma platelet-activating factor acetylhydrolase. Purification and properties. J Biol Chem. 262:4215-4222.
72. Stafforini DM. (2009). Biology of platelet-activating factor acetylhydrolase (PAF-AH, lipoprotein associated phospholipase A2). Cardiovasc Drugs Ther 23:73-83.
73. Stafforini DM, Tjoelker LW, McCormick SP, Vaitkus D, McIntyre TM, Gray PW, Young SG, Prescott SM. (1999). Molecular basis of the interaction between plasma platelet-activating factor acetylhydrolase and low density lipoprotein. J Biol Chem 274:7018-7024.
74. Steinberg D. (2009). The LDL modification hypothesis of atherogenesis: an update. J Lipid Res 50 Suppl:S376-S381.
75. Suckling K. (2010). Phospholipase A2s: developing drug targets for atherosclerosis. Atherosclerosis 212:357-366.
76. Sumita C, Maeda M, Fujio Y, Kim J, Fujitsu J, Kasayama S, Yamamoto I, Azuma J. (2004). Pioglitazone induces plasma platelet activating factor-acetylhydrolase and inhibits platelet activating factormediated cytoskeletal reorganization in macrophage. Biochim Biophys Acta 1673:115-121.
77. Suzuki T, Solomon C, Jenny NS, Tracy R, Nelson JJ, Psaty BM, Furberg C, Cushman M. (2009). Lipoprotein-associated phospholipase A(2) and risk of congestive heart failure in older adults: the Cardiovascular Health Study. Circ Heart Fail 2:429-436.
78. Takahashi M, Okazaki H, Ogata Y, Takeuchi K, Ikeda U, Shimada K. (2002). Lysophosphatidylcholine induces apoptosis in human endothelial cells through a p38-mitogen-activated protein kinase-dependent mechanism. Atherosclerosis 161:387-394.
79. Tew DG, Southan C, Rice SQ, Lawrence MP, Li H, Boyd HF, Moores K, Gloger IS, Macphee CH. (1996). Purification, properties, sequencing, and cloning of a lipoprotein-associated, serinedependent phospholipase involved in the oxidative modification of low-density lipoproteins. Arterioscler Thromb Vasc Biol 16:591-599.
80. The Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy Trial (STABILITY). http://clinicaltrials.gov/ct2/show/NCT 00799903?term=darapladib&rank=7; Last Updated on December 1, 2011
81. The Stabilization of pLaques usIng Darapladib-Thrombolysis In Myocardial Infarction 52 Trial (SOLID-TIMI 52). http:// clinicaltrials.gov/ct2/show/ NCT01000727?term=darapladib&ra nk=8; Last Updated on December 1, 2011
82. Thompson A, Gao P, Orfei L, Watson S, Di Angelantonio E, Kaptoge S, Ballantyne C, Cannon CP, Criqui M, Cushman M, Hofman A, Packard C, Thompson SG, Collins R, Danesh J; Lp-PLA(2) Studies Collaboration. (2010). Lipoprotein-associated phospholipase A(2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet 375:1536-1544.
83. Tselepis AD, Hahalis G, Tellis CC, Papavasiliou EC, Mylona PT, Kourakli A, Alexopoulos DC. (2010). Plasma levels of lipoproteinassociated phospholipase A(2) are increased in patients with s-thalassemia. J Lipid Res 51:3331-3341.
84. Tsimihodimos V, Karabina SA, Tambaki AP, Bairaktari E, Goudevenos JA, Chapman MJ, Elisaf M, Tselepis AD. (2002). Atorvastatin preferentially reduces LDL-associated platelet-activating factor acetylhydrolase activity in dyslipidemias of type IIA and type IIB. Arterioscler Thromb Vasc Biol 22:306-311.
85. Tsimikas S, Willeit J, Knoflach M, Mayr M, Egger G, Notdurfter M, Witztum JL, Wiedermann CJ, Xu Q, Kiechl S. (2009). Lipoproteinassociated phospholipase A2 activity, ferritin levels, metabolic syndrome, and 10-year cardiovascular and non-cardiovascular mortality: results from the Bruneck study. Eur Heart J 30:107-115.
86. Wilensky RL, Shi Y, Mohler ER 3rd, Hamamdzic D, Burgert ME, Li J, Postle A, Fenning RS, Bollinger JG, Hoffman BE, Pelchovitz DJ, Yang J, Mirabile RC, Webb CL, Zhang L, Zhang P, Gelb MH, Walker MC, Zalewski A, Macphee CH. (2008). Inhibition of lipoproteinassociated phospholipase A2 reduces complex coronary atherosclerotic plaque development. Nat Med 14:1059-1066.
87. Winkler K, Winkelmann BR, Scharnagl H, Hoffmann MM, Grawitz AB, Nauck M, Bohm BO, Marz W. (2005). Platelet-activating factor acetylhydrolase activity indicates angiographic coronary artery disease independently of systemic inflammation and other risk factors: the Ludwigshafen Risk and Cardiovascular Health Study. Circulation 111:980-987.
88. Winstead MV, Balsinde J, Dennis EA. (2000). Calcium-independent phospholipase A(2): structure and function. Biochim Biophys Acta 1488:28-39.
89. Yamada Y, Ichihara S, Fujimura T, Yokota M. (1998). Identification of the G994-> T missense in exon 9 of the plasma plateletactivating factor acetylhydrolase gene as an independent risk factor for coronary artery disease in Japanese men. Metab Clin Exp 47:177-181.
90. Yoshimura T, Ohshige A, Maeda T, Ito M, Okamura H. (1999). Estrogen replacement therapy decreases platelet-activating factoracetylhydrolase activity in post-menopausal women. Maturitas 31:249-253.
91. Zalewski A, Macphee C. (2005). Role of lipoprotein-associated phospholipase A2 in atherosclerosis: biology, epidemiology, and possible therapeutic target. Arterioscler Thromb Vasc Biol 25:923-931.